Salvage Chemotherapy Following Osimertinib in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation

Salvage Chemotherapy Following Osimertinib in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation - Salvage Chemotherapy Following Osimertinib in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039044

Enrollment

Registered

2020-01-02

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study includes advanced-NSCLC patients who received osimertinib treatment between June 2016 and July 2019 in our institution and were treated with salvage chemotherapy after getting resistance to osimertinib.

Exclusion criteria

Exclusion criteria: Patients or their family refuse to participate in this study.

Design outcomes

Primary

Measure	Time frame
The treatment efficacy of salvage chemotherapy after resistance to osimertinib in NSCLC patients.	—

Secondary

Measure	Time frame
The adverse events of salvage chemotherapy after resistance to osimertinib in NSCLC patients.	—

Countries

Japan

Contacts

Public ContactMari Tone

Japanese Red Cross Medical Center Department of Respiratory Medicine

m.tone.0829@gmail.com03-3400-1311

Outcome results